TEMPEST THERAPEUTICS INC. - COMMON STOCK

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

27 Apr 2023 15:58:11 By Nasdaq GlobeNewswire

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

26 Apr 2023 17:41:26 By Nasdaq GlobeNewswire

Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting

17 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Tempest Reports Year End 2022 Financial Results and Provides Business Update

22 Mar 2023 16:26:49 By Nasdaq GlobeNewswire

Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting

15 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

14 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

22 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer

10 Nov 2022 08:00:02 By Nasdaq GlobeNewswire

Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting

02 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

06 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 07:00:03 By Nasdaq GlobeNewswire

Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update

15 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference

07 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance

09 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Tempest to Present at the Jefferies Healthcare Conference

06 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting

26 May 2022 15:57:40 By Nasdaq GlobeNewswire

Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights

13 May 2022 07:00:00 By Nasdaq GlobeNewswire

Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting

27 Apr 2022 09:01:00 By Nasdaq GlobeNewswire

Tempest Announces Private Placement Financing of $15 Million

27 Apr 2022 07:00:02 By Nasdaq GlobeNewswire